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Background. Carotid angioplasty (CA) has been suggested to be a safer and more cost- 
effective alternative to carotid endarterectomy (CEA) in the management of sympto- 
matic severe internal carotid artery (ICA) disease. 
Methods.. The study was conducted as a prospective consecutive randomized trial of CEA 
versus CA for symptomatic severe IGA disease in a university teaching hospital. All 
patients were assessed before and after surgery by a neurologist. The study consisted of 
23 patients with focal carotid territory symptoms and severe ICA stenosis (> 70%) who 
were randomized to either CEA or CA. However, only 17 had received their allocated 
treatment before trial suspension. CEA with patching or CA with stenting were used as 
interventions. The main outcome measures were death or disabling or nondisabling 
stroke within 30 clays. 
Remlu.- All 10 CEA operations proceeded without complication, but 5 of the 7 patients 
who underwent CA had a stroke (P - .0034), 3 of which were disabling at 30 days. 
Conclusions: After referral, the Data Monitoring Committee invoked the stopping rule 
and the trial was suspended. The investigators and the Ethics Committee subsequently 
concluded that the trial could not be restarted--even in an amended format~primarily 
because of problems with informed consent. We review many of the ethical dilemmas 
encountered in the performance of this study. I f  future trials do suggest a selected role 
for CA, it is essential that both the inclusion and the exclusion criteria are fully docu- 
mented. (J Vase Surg 1998;28:326-34.) 
Carotid endarterectomy (CEA) has a proven 
benefit in symptomatic severe internal carotid artery 
(ICA) disease.la The awareness of  this benefit has 
led to increases in operative workload. 3 However, 
concerns remain about its cost-effectiveness and 
whether the results from the use of selected surgeons 
and centers in the International Trials can be used to 
justify clinical practice by all surgeons in all centers. 4 
Angioplasty to the peripheral arteries--excluding 
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the cranial circulation--was introduced in the 1970s 
to widespread concern by vascular surgeons who 
assumed that it would cause an unacceptable 
increase in morbidity and mortality rates. However, 
time has shown it to be an effective treatment s rat- 
egy, and, without our radiology colleagues, most 
vascular surgeons would be unable to cope with 
their current claudication and critical ischemia work- 
load. Subsequent experience with carotid angioplas- 
ty (CA), which had previously been avoided by 
many clinicians because of the potential for embolic 
stroke, prompted an overview by Brown s of  the 
published results of CA up to 1992. This overview 
suggested that CA was, in fact, associated with a 
major stroke risk of 1%, s which was surprisingly less 
than the 2% stroke rate associated with carotid 
angiography alone in patients who were sympto- 
matic. 6 This favorable overview thereafter became 
the catalyst for the randomized, but selective, 
Carotid and Vertebral Artery Transluminal 
Angioplasty Study (CAVATAS) trial7 and provoked 
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considerable debate about the ethics and methodol- 
ogy of randomized trials of CEA versus CA. sql 
Our opinion has remained, however, that we 
must be aware of both inclusion and exclusion crite- 
ria 9 to permit meaningful interpretation f any ran- 
domized trials of CA and CEA, so that the results 
can thereafter be applied to clinical practice. This is 
in accordance with the Consolidated Standards of 
Reporting Trials (CONSORT) statement on the 
performance of randomized trials.12 Thus, the trial 
reported in this paper chose to randomize patients 
who were symptomatic and who fulfilled our criteria 
for undergoing CEA, on the basis that there was 
currently no reliable method of excluding high-risk 
patients, plaques, or luminal thrombus. 
MATERIAL AND METHODS 
Inclusion and exclusion criteria. The patients 
underwent clinical assessment, duplex examination, 
and risk factor profiling in a singie-visit clinic. Those 
patients with carotid territory symptoms and evidence 
of an ipsilateral 70% to 99% ICA stenosis were ran- 
domimd to optimal medical therapy with either CEA 
or CA after giving informed consent. Specific exclu- 
sion criteria included patients with asymptomatic dis- 
ease, symptomatic 0% to 69% stenosis, crescendo tran- 
sient ischemic attack (TIA) or stroke in evolution, and 
vertebrobasilar o nonhemispheric symptoms and 
those patients who refused to give informed consent. 
Permission to perform this study was given by the 
Leicestershire Area Ethics Committee, and the trial 
was monitored by an independent data monitoring 
committee (DMC). 
Patient recruitment and randomization. Three 
hundred random treatment methods were numbered 
and sealed in opaque envelopes and allocated on a 
consecutive basis starting with envelope number 1. 
Between June 15, 1996, and September 12, 1996, 23 
patients were randomized to CA (n., 11) or CEA (n 
= 12), but only 17 received their treatment before 
trial suspension (CEA = 10, CA = 7). Three patients 
were excluded from the trial after randomization; 1 
patient, fi~r CEA, occluded his ICA asymptomatically 
before admission, and 2, for CEA and CA, refused to 
undergo their allotted treatment after admission. 
Another 3 patients were awaiting admission when the 
trial was suspended. Four patients who were sympto- 
matic wcre not randomized in the trial and under- 
went an uneventful CEA during the period the trial 
was being performed; 2 patients were first seen with 
crescendo TIAs, 1 declined to participate in the trial, 
and 1 opted to have his surgery perfi~rmed privately 
in another hopital. 
Assessment before surgery. The carotid arteries 
were examined before randomization a d again after 
admission with an ATL Ultramark (Bothel, Wash.) 
with video-recording for off-line analysis. The vascu- 
lar technologists, who had 2 to 12 years of duplex 
scanning experience, recorded the following: (1) the 
degree of stenosis with angle-corrected Doppler 
scanning; (2) a pictorial, longitudinal, and transverse 
representation of the plaque to include details of like- 
ly thrombus, ulceration and calcification, and plaque 
length; and (3) the Gray-Weale 13plaque morpholo- 
gy score (type 1, echolucent; type 2, predominantly 
echolucent; ype 3, predominantly echogenic; and 
type 4, echogenic) and the Lusby 14 surface feature 
score (type 1, smooth; type 2, irregular; type 3, ulcer- 
ated; type 4, ulcerated plus thrombus; and type 5, 
thrombus but no ulceration). In this center, a com- 
bination of B-mode imaging plus an angle-corrected 
peak systolic velocity more than 200 cm/sec and an 
end-diastolic velocity more than l l0cm/sec was 
used to diagnose an ICA stenosis > 70%. All patients 
were seen and examined by a neurologist, and all 
underwent cognitive assessment bya psychologist. 
Carotid endarterectomy. Administration of 
aspirin was not stopped before surgery. CEA was 
performed by a consultant (n = 5) or by a supervised 
trainee (n .. 5) with normotensive, normocarbic 
general anaesthesia that used systemic heparinization 
(5000 units), loupe magnification, routine patching 
(collagen-coated Dacron graft), and routine shunt- 
ing (Pruitt-lnahara, Ideas for Medicine, Fla.) with 
tacking sutures to the distal intimal step. Blood flow 
velocity in the ipsilateral middle cerebral artery was 
monitored with transcranial Doppler (TCD) ultra- 
sound scan with a fixed head-probe system (Scimed 
UK Ltd, Bristol, UK), with recording onto digital 
audiotape for off-line analysis of emboli. Is Before 
restoration of flow, all vessels were inspected with an 
angioscope to exclude technical error. 16 After the 
procedure, TCD monitoring was continued for 6 
hours. Previous studies have shown that sustained 
microembolization is highly predictive of postopera- 
tive thrombosis]7,18 but that dextran therapy can 
prevent his from developing. 19 Accordingly, any 
patient who had evidence of more than 25 emboli 
during any 10-minute period of monitoring was 
started on an incremental intravenous infusion of 
dextran-40. ]9 
Carotid angioplasty. The consultant radiologist 
who performed the CA in this study had a personal 
experience of more than 4000 angioplasties to the 
peripheral arteries, which included more than 500 
within the tibia/or pedal circulation. In addition, 8 
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Table I. Details of patients who underwent carotid endarterectomy 
Sex Age No of i~ehemic Time since most I CA stenosis Gra~-Weak Lusby 
(M/F) (years) Presentation events recent event (PSV) * scale score 
F 71 TIA 1 5 months 80% (350 cm/s) 2 2 
M 74 Stroke 1 7 months 80% (315 cm/s) 3 2 
M 68 TIA 3 3 months 85% (420 cm/s) 2 2 
F 68 Amaurosis 1 5 months 70% (220 cm/s) 3 3 
F 76 Stroke 1 6 months 70% (227 cm/s) 2 2 
M 54 Stroke and deficit 1 2 months 90% (450 cm/s) 1 1 
M 59 Amaurosis 1 3 months 90% (400 cm/s) 2 3 
F 67 Stroke 2 1 month 95% (479 cm/s) 2 2 
F 63 TIA 1 3 weeks 80% (350 cm/s) 3 2 
F 67 Amaurosis >10 2 days 75% (250 cm/s) 3 2 
ICA, internal carotid artery; PSV, peak s3,stolic velocity with angle-corrected Doppler scanning; T/A, transient ischemic attack. 
tmcomplieated but selected CAs had been performed 
by this radiologist before starting the study. Aspirin 
therapy was not stopped before CA. The common 
femoral artery was cannulated with the Seldinger tech- 
nique, and a standard guidewire was passed into the 
aortic arch. The appropriate common carotid artery 
was cannttlated with a hydrophilic guidewire and with 
a selective vertebral catheter passed over the wire to 
permit carotid angiography and road mapping. The 
patient systemically received heparin (5000 IU) and 
600 ~tg of atropine befbre any balloon inflation. After 
the carotid angiogram; the radiologist estimatcd the 
length and severity of the lesion and the length and 
size of the stent required. The principle of primary 
stenting, as practiced by Mathias, 2° was followed 
thereafter. If any resistance was noted to the passage 
of the stent catheter across the lesion, the stenosis 
was predilated with a 4-mm diameter angioplasty bal- 
loon. After this, or as a primary procedure, a self- 
expanding WaUstent (Schneider, Minneapolis, Minn) 
was positioned across the leskm and deployed. Once 
the stent had been deployed, the lesion was dilated 
with an appropriately sized balloon (usually 6-mm 
diameter) to permit full expansion of the stent with- 
in the ICA. Up to 3 balloon inflations~no more 
than 15 seconds apiece~were permitted. After 
an~oplasty/stent deployment, a completion angio- 
gram was performed. TCD monitoring was per- 
formed throughout the procedure and for 6 hours 
after surgery. Our protocol required the administra- 
tion ofdextran-40 with the same criteria as described 
above for CEA. 
Assessment after surgery. Patients were re- 
examined by a consultant neurologist 24 hours after 
intervention, and any new neurologic deficit was 
recorded. A stroke was defined as any new neuro- 
logic deficit persisting for more than 24 hours. The 
neurologist reassessed all patients at 30 days where 
an Oxfordshire Handicap Stroke score was made. A 
minor (nondisabling stroke) scored a 0 to a 2 on this 
scale, and a disabling stroke scored a 3 to a 6. 21 
Statistical analysis. The Ethics Committee 
required the DMC to perform interim analyses after 
every 20 patients were treated. Because we recog- 
nized that repeated analyses might influence the 
overall level of significance, we used the group 
sequential method. 22 In this method, a predeter- 
mined significance l vel of P < .0086 was to be used 
at each of the 15 interim analyses to achieve an over- 
all significance l vel of P< .05, at the end of the trial. 
Therefbre, the DMC were informed that should any 
interim analyses yield a significance level of P < 
.0086, the stopping rule should apply.22 
RESULTS 
Carotid endarterectomy. The presenting cLini- 
cal features, numbers, and timing of cerebral 
ischemic events, together with the degree of ICA 
stenosis and the Gray-Weale and Lusby plaque classi- 
fications, are detailed h~ Table I. All patients under- 
went an uneventful operation that lasted a median 
length of 112 minutes (range, 89 to 128 minutes), 
and all were dischargcd home on day 5. No deaths 
occurred within 30 days, and no new operation-relat- 
ed neurologic deficits or cranial nervc injuries were 
seen. The median number of cerebral emboli detect- 
ed during the entire procedure was 12 (range, 0 to 
26). No technical error was detected after comple- 
tion angioscopy, no patient had sustained emboliza- 
rion in the early lX~stoperativc period, and no case 
received adjuvant dextran therapy. None of the 4 
patients who were symptomatic and who underwent 
CEA throughout the trial suffered a perioperative 
stroke. 
Carotid angioplasty. The presenting clinical fea- 
tures, numbers, and timing of cerebral ischemic 
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Fig. 1. Angiograms before angioplasty. Cases correspond to case numbers in Tables II and III. 
Cases 1 through 4 are on top from left to right, and cases 5through 7 are on bottom from left 
to right. Note that in case 5, the pinhole lumen (arrow) is not readily apparent in this image. 
~.. ~,~ 
events, together with the degree ofICA stenosis and 
the Gray-Weale and Lusby plaque classifications, are 
detailed in Table II. Figs. 1 and 2 illustrate ach of the 
carotid stenoses before and after CA. The median 
duration of the CAwas 45 minutes (range, 35 to 103 
minutes). Five of the 7 CAs required predilatation 
before stent insertion (cases 2, 3, and 5-7). The medi- 
an number of cerebral emboli detected uring CA 
was 284 (range, 151 to 379), which was significantly 
higher than the rate of embolization observed uring 
CEA (P = .0015, Mann-Whitney). "Fable II summa- 
rizes the numbers of emboli detected at each stage of 
the angioplasty. None of the CA patients died within 
30 days, but 5 suffered ipsilateral stroke, although 
none were hemorrhagic on computed tomography 
scanning. Four strokes occurred during angioplasty, 
and 1 patient was readmitted on day 8 with a nondis- 
abling stroke. None of the patients with a stroke had 
any obvious abnormality of the stented ICA on 
duplex scanning. Overall, 3 of the 5 procedural 
strokes were disabling at 30 days (herniparesis/hemi- 
plegia ± dysphasia [n = 2], aphasia [n = 1]), and while 
2 were non-disabling (hemiparesis [n = 2]). 
Referral to the data monitoring committee. 
In accordance with the wishes of the Ethics 
Committee, we had intended to complete 20 inter- 
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Fig. 2. Angiograms aftcr angioplas~. Cases are in same sequence as in Fig. 1 to permit com- 
parison. 
ventions before the DMC performed its first inter- 
im analysis. However, although the first 2 CA 
patients in the trial suffered no adverse vents, the 
next 5 patients uffered CA-related strokes, which 
was a highly significant risk of adverse outcome as 
compared with CEA (P = .0034, Fisher exact Test). 
Therefore, the results were passed onto the DMC 
who met and subsequently invoked the stopping 
rule pending formal review of all of the data. After 
much deliberation, the investigators and the Ethics 
Committee concluded that the trial could not be 
restarted, even in a revised format, primarily 
because of problems with a informed consent o 
future CA patients. The trial was officially aban- 
doned in April 1997. 
DISCUSSION 
This trial has highlighted anumber of issues, not 
least of which are the conflict between individual 
and collective thics, the role of DMCs regarding 
stopping rules, the interpretation ofinterim analyses, 
and the principles of informed consent. However, 
because the trial was stopped early, it will inevitably 
be associated with a number of disadvantages that 
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Table IT. Details of patients who underwent carotid angioplasty 
Sex Age No of ischemic Time since most ICA stenosis Gray- Weale Lusby 
(M/F) (years) Presentation events recent event (months) (PSV) * scale score 
M 63 Stroke and deficit 1 8 75% (300 cm/s) 2 2 
F 51 Stroke 1 7 80% (280 cm/s) 4 2 
M 78 TIA 3 1 9056 (550 c.m/s) 1 1" 
F 68 Stroke and deficit 2 10 95% (550 cm/s) 2 2* 
M 72 Amaurosis 1 1 70% (203 cm/s) 4 UK* 
M 70 TIA 1 1 90% (450 cm/s) 1 2" 
M 74 Stroke 1 3 80% (260 cm/s) 3 2* 
/CA, internal carotid artery; PSV,, peak systolic velocity with angle-corrected Doppler scanning; UK, unable to determine Lusby score 
accu~t¢~. 
*Patients who underwent carotid angioplasty and had a proccdural stroke. 
Table HI. Number of emboli detected uring carotid angioplasty 
Number of emboli 
Time of detection of emboli Case I * Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 
Manipulation of wire across tenosis 29 20 115 50 71 158 115 
Balloon predilatation 01" 56 21 01" 60 42 1 
Stem deployment 125 90 110 65 159 76 115 
Balloon inflation 1 28 23 14 29 0 0 
Balloon deflation 26 81 101 22 60 86 53 
Total cmboli 181 275 370 15l 379 362 284 
OHS stroke score at 30 days No CWA No CVA 3~ 0~ 2:I: 3:[: 3::[: 
OH.q, Oxfordshirc Handicap Scale; CVA, cerebral vascular accident. 
*Also refer to Fig. 1. 
"['No balloon predilatation. 
~:Stroke occurred uring angioplasty. 
§Stroke occurred on day 8 after CA. 
were summarized by Pocock as: (1) a lack of credi- 
bility because small trials are not usually statistically 
convincing, (2) a lack of realism because major treat- 
ment differences seem implausible, (3) imprecision 
because of the wide confidence intervals, (4) bias 
because suspended trials tend to stop on a random 
high or low level, (5) pressure to produce inappro- 
priate recommendations r conclusions, and (6) the 
increased risk of a false-positive r sult. 23 We have 
therefore avoided sweeping conclusions after the 
suspension of this trial but would hope that some of 
its findings and implications are borne in mind when 
interpreting the results of other studies. 
Our trial was designed and implemented after 
publication of an overview that suggested that CA 
was associated with a 1% risk of major stroke, s 
Others have since reported procedural stroke rates 
which, like ours, were significantly higher.24, 2s
Despite this, the principal criticism of our study will 
be the premature suspension after an adverse interim 
analysis (ie, the 70% stroke rate after CA represent- 
ed a chance finding, and we should have continued 
recruiting patients). Moreover, because the Ethics 
Committee required the DMC to perform 15 
planned interim analyses during the study, we may 
have compounded this error because the chance of 
encountering at least 1 statistically significant result 
is increased by repeated analyses. 26 
The problem of fTequent analyses was, however, 
recognized by us from the outset, and, in accordance 
with statistical practice, we adopted one of the group 
sequential methods for use in the trial.22 Thus, the 
DMC operated a stopping rule that required any one 
of the predetermined interim analyses to have a P 
value eft< .0086 to minimise the risk of a type I error 
to less than 5%. Moreover, at the time of planning 
our trial, we did not allow for a lower statistical sig- 
nificance level to be used for early stopping in the 
event of excessive adverse events occurring. 
However, this is also accepted statistical practice (ie, 
the degree of evidence required to suspend a trial 
that shows a harmful effect is less than that required 
to show a beneficial effect). 27 If we had thereafter 
chosen to ignore these arly adverse results, we faced 
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major problems regarding future informed consent. 
If the results of the trial to date were thereafter quot- 
ed (individual ethics), no one would have agreed to 
participate. I f we had quoted overviews from the lit- 
erature to justify recruitment (collective thics), we 
might have been liable to legal action for not quot- 
ing the true risk of CA in our center. In this respect, 
we are sure we are not the only center to have faced 
this fundamental, but unanswered, problem. To 
counter the problem of individual ethics within a sin- 
gle-center t ial, it might be argued that, had we par- 
ticipated in a multi-center t ial, the principle of col- 
lective ethics might have been able to run to its com- 
pletion. However, had we been one of the many 
contributors to a larger trial, we would have simply 
withdrawn, given our complication rate (ie, it is not 
inconceivable that the results of such a trial could 
mask the fact that centers with adverse results tend to 
withdraw leaving an unspecified number of more 
successful centers to complete the trial). Clearly, 
there is no perfect solution. 
Others may argue that CFAk and CA should not 
• be subjected to randomized comparison s and that 
even if comparison were to occur, now would not 
the appropriate time. However, in this era of evi- 
dence-based medic!ne, any new, and potentially 
risky, intervention must be subjected to randomized 
comparison with the current gold standard and not 
simply evolve as accepted practice on the basis of 
selected case series compared with historical con- 
trois. Ironically, although the current debate con- 
cerns CA, the latter criticism was also leveled against 
CEA before the trials confirmed its proven role in 
selected patients. 28 Moreover, because United 
Kingdom healthcare purchasers do not fund experi- 
mental procedures and because hospitals will not 
legally indemnify clinicians unless new interventions 
have been reviewed and approved by the regional 
Ethics Committee, there are compelling clinical, 
financial, ethical, and legal reasons for insisting that 
few CAs be performed throughout randomized tri- 
als. Critics may also argue that our timing was wrong 
because the trial did not allow for future advances in 
catheter technology. In our opinion, there will never 
be an optimal time and this argument could be 
applied ad infinitum. 
It could also be debated that our results simply 
represent a learning curve or poor technique that 
will otherwise improve with time. Although we 
accept hat all new techniques invoke a learning 
curve, our experienced vascular adiologist saw no 
complications after CA in 8 highly selected patients 
(single cerebral ischemic event, very smooth 
stenoses on duplex scan, and nonurgent presenta- 
tion) in the 4 months before the trial, and inexperi- 
ence was no bar to participating in CAVATAS. 
Perhaps most importantly, it should be noted that if 
CA is to become widely accepted, the learning curve 
will apply to all current interventional radiologists 
and continue to apply to all future generations of 
radiologic trainees (as it already does to surgeons). 
Therefore, unless CAs are to be performed by a 
small group of radiologists, the discussion of proce- 
dural risk must include an allowance for training risk, 
something which has never been debated in any of 
the published CA series to date. Paradoxically, the 
learning curve is probably less of a problem with 
CEA because it is undertaken i  a more controlled 
environment, with numerous quality control and 
monitoring techniques to reduce the risk of inadver- 
tent technical error. 29 In this series, 50% of the 
CEAs were performed by trainees, which is in accor- 
dance with our usual clinical practice. In 1996, 82 of 
151 CEAs were performed by supervised trainees, 
with a death/any strokc rate of 2.4%; the overall 
stroke rate for the unit during 1996 was 1.4%. 29 
Accordingly, when surgical risk is discussed with 
patients in our institution, this already takes into 
account an allc~wance for the learning curve of our 
surgical trainees. 
Regarding our choice of technique, we reviewed 
the experiences of many centers before we under- 
took this trial. We ultimately adopted the method 
described by Mathias 2° after a visit to his unit, which 
uses predilatation, if necessary, and primary stent- 
ing. ~° Although we considered the possibility of bal- 
loon angioplasty alone or the tri-axial system, which 
incorporates a protective distal balloon, 30 there was 
a prevailing opinion at the time that primary stent- 
ing was probably preferable. Although stent deploy- 
ment was associated with a large amount of 
embolization (Table III), we are aware of no evi- 
dence that our choice of CA method was otherwise 
inappropriate. However, 4 of the 5 patients who 
required predilatation suffered a stroke during 
surgery in our series. In theory, predilatation should 
be no different to primary balloon angioplasty, but it 
does suggest hat patients with very severe disease 
and a small residual lumen may be at particular isk 
as the balloon catheter/stent combinations are 
invariably wider that the residual ICA lumen. 
The penultimate criticism is likely to be that we 
not only selected the wrong patients for inclusion 
but that it was unethical to perform a randomized 
trial in every patient with symptomatic carotid artery 
disease who would otherwise have undergone CEA. 
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In CAVATAS, the exclusion criteria are not stan- 
dardized and are left to the discretion of the partici- 
pating centers. However, each center is advised not 
to include patients with possible luminal thrombns. 
This is a crucial issue that incurs much debate,S, 9 but 
the simple fact remains that neither angiography nor 
duplex ultrasound scan can reliably identify luminal 
thrombus. In the real world, the clinician is faced 
with a patient who is symptomatic with a severe 
carotid stenosis and that clinican has to make a deci- 
sion regarding management. Despite protestations 
to the contrary, relatively few patients will be unsuit- 
able for CEA and the presence or absence of  luminal 
thrombus is never a contraindication for operation. 
As such, if CAVATAS were indeed to recommend 
CA in some patients and not in others, it is impera- 
tive that we are all aware of  reliable inclusion and 
exclusion criteria so that they can be applied safely in 
our day-to-day practice. 
Finally, because we have suspended the trial, it 
might be argued that the investigators should either 
have resurrected it in an amended format or consid- 
ered joining CAVKI'AS. We did, in fact, consider an 
amended protocol in which patients with a 70% to 
90% stenosis and a residual umen of more than 2 
mm were randomized. However, we again encoun- 
tered major problems concerning informed consent 
about procedural risk, the scientific basis for exclud- 
hag >90% stenoses, and pertbrmance of  contrast 
angiography on all patients to select those suitable 
fbr inclusion. In addition, the Ethics Committee 
now wished the chairman of the DMC to review the 
results after each individual case. The principle of 
informed consent proved to be a particular problem, 
particularly as our overall stroke risk after CEA had 
fallen to 1.4% by December 1996. 29 Moreover, 
because fewer than 5% of  our patients for CEA now 
undergo routine preoperative angiography, ~1per- 
forming angiography on all patients to select hose 
suitable for inclusion would have further increased 
the overall morbidity rate because of  the 2% 
angiogram-rclatcd stroke risk. 6 As a consequence, 
efforts to resurrect the trial in an amended format 
were abandoned. Similarly, we considered joining 
CAVATAS, but in view of  our documented con- 
cerns, 9we declined. In short, we were concerned by 
the lack of  standardized inclusion criteria within 
CAVATAS, however understandable, and a failure to 
record which patients were excluded from the trial, 
and upon which grotmds, which is clearly contrary 
to the CONSORT recommendations, lz Finally, 
although participating CAVATAS centers were per- 
mitred to present heir own angioplasty experience 
at national and international symposia, we were con- 
cemed that these "interim" presentations and publi- 
cationsS2, 3a had the potential--however uninten- 
tionalmto influence patient recruitment in other less 
experienced centers. For example, would your clini- 
cal equipoise remain unchanged so as to allow you 
to continue to randomize patients in an unbiased 
fashion if you subsequently discovered that 2 of  the 
largest and most experienced CAVATAS centers had 
reported a combined eath and stroke rate of 8% 
after angioplasty, 3~particularly ifyou knew that your 
own complication rate after CEA was lower? 
In conclusion, although CA undoubtedly has 
attractive theoretical benefits over CEA, our trial 
suggests that it cannot be used routinely in patients 
with symptomatic carotid artery disease who would 
otherwise undergo CEA. All of  those patients who 
underwent CA and suffered aprocedural stroke had 
no obvious angiographic or duplex-scan evidence of  
a high-risk plaque, and all represented the standard 
type of  patient encountered in our routine carotid 
surgical practice. Therefore, if CA is to have a future 
role, it must be proven in randomized trials that 
conform to the CONSORT criteria and in a manner 
that takes into account the variability associated with 
all patients, all centers, and all radiologists. 
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